Who should not take GHRP-2 / GHRP-6?
Documented caution flags for GHRP-2 / GHRP-6 include active malignancy and pregnancy / nursing. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for GHRP-2 / GHRP-6 is limited.
Documented caution flags for GHRP-2 / GHRP-6
- Active malignancy
- Pregnancy / nursing
Reported side effects to weigh
- GHRP-6: aggressive hunger 30-60 min post-dose
- GHRP-2: cortisol and prolactin bumps
- Head-rush at injection
- Receptor desensitization with chronic use
References
- Effects of GH-releasing peptide-2 (GHRP-2) on body composition — Bowers CY et al., JCEM, 2004
- Estradiol regulates GH-releasing peptide's interactions with GH-releasing hormone and somatostatin in postmenopausal women — Norman C et al., European Journal of Endocrinology, 2014
- Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy — Broglio F et al., Endocrine, 2001
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on GHRP-2 / GHRP-6
Last updated 2026-06-15.